These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17119491)

  • 21. Olanzapine for primary negative symptoms.
    Licht RW
    Am J Psychiatry; 1998 Aug; 155(8):1133-4. PubMed ID: 9699711
    [No Abstract]   [Full Text] [Related]  

  • 22. [Deficit schizophrenias].
    Puech AJ
    Encephale; 1996 Jun; 22 Spec No 2():1. PubMed ID: 8767033
    [No Abstract]   [Full Text] [Related]  

  • 23. Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    J Clin Psychopharmacol; 2005 Aug; 25(4):293-300. PubMed ID: 16012270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clozapine: efficacy and safety.
    Buchanan RW
    Schizophr Bull; 1995; 21(4):579-91. PubMed ID: 8749886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic maintenance treatment of schizophrenia patients: is there a consensus?
    Meise U; Kurz M; Fleischhacker WW
    Schizophr Bull; 1994; 20(1):215-25. PubMed ID: 7910977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of negative symptoms: pharmacological and methodological issues.
    Carpenter WT
    Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
    Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
    Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice].
    Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC
    Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment effectiveness in patients with schizophrenia as measured by the ASSESS battery - first longitudinal data.
    Ladea M; Barbu CM; Juckel G
    Psychiatr Danub; 2015 Dec; 27(4):364-70. PubMed ID: 26609648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The course of the first schizophrenic illness. A 5-year catamnesis].
    Fähndrich E; Richter S
    Nervenarzt; 1986 Dec; 57(12):705-11. PubMed ID: 2881221
    [No Abstract]   [Full Text] [Related]  

  • 31. Original research paper. Switching antipsychotics: Results of 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders.
    Bole CB; Pišlar M; Šen M; Tavčar R; Mrhar A
    Acta Pharm; 2017 Mar; 67(1):99-112. PubMed ID: 28231044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of second-generation antipsychotics in the treatment of psychotic disorders.
    Jackson CW
    Am J Health Syst Pharm; 2007 Apr; 64(8):815. PubMed ID: 17420195
    [No Abstract]   [Full Text] [Related]  

  • 33. [Factors related to treatment adherence in schizophrenic patients].
    García Cabeza I; Sánchez Díaz EI; Sanz Amador M; Gutiérrez Rodríguez M; González de Chávez M
    Actas Esp Psiquiatr; 1999; 27(4):211-6. PubMed ID: 10469940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nemonapride for the treatment of schizophrenia.
    Satoh K; Someya T; Shibasaki M
    Am J Psychiatry; 1997 Feb; 154(2):292. PubMed ID: 9016292
    [No Abstract]   [Full Text] [Related]  

  • 35. The MATRICS consensus cognitive battery: what we know 6 years later.
    Green MF; Harris JG; Nuechterlein KH
    Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
    [No Abstract]   [Full Text] [Related]  

  • 36. Treating negative symptoms.
    Bailey P; Duval F; Macher JP
    Br J Psychiatry; 1994 May; 164(5):699-700. PubMed ID: 7921730
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pharmacotherapy for schizophrenia].
    Fleischhacker WW; Hummer W
    Nervenarzt; 2006 Nov; 77 Suppl 2():S77-97; S98. PubMed ID: 17082927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS; Last B; Getson A; Reines SA
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early prediction of antipsychotic response in schizophrenia.
    Correll CU; Malhotra AK; Kaushik S; McMeniman M; Kane JM
    Am J Psychiatry; 2003 Nov; 160(11):2063-5. PubMed ID: 14594760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
    Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
    J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.